Asymptomatic Carotid Surgery Trial ACST-2 Collaborators Meeting 2014 Pembroke College, Oxford Is recent coronary stenting a problem (or an opportunity)

Slides:



Advertisements
Similar presentations
MAIN-COMPARE Study – Disclosure Information
Advertisements

Leadership. Knowledge. Community. Canadian Cardiovascular Society Antiplatelet Guidelines PERIOPERATIVE MANAGEMENT OF ANTIPLATELET THERAPY Working Group:
Stenting Patients Needing Non-Cardiac Surgery
CABG VS Multi Vessel PCI Hasanat Sharif MD FRCS Chief of Cardiorthoracic Surgery Aga Khan University Hospital.
Cardiology Morning Report: Revascularization in Stable Ischemic Heart Disease Bobby Mathew, MD LSU Internal Medicine, HO-II.
Can we prevent stent restenosis after coronary stent implantation
CABG GUIDELINES SANJAY DRAVID, M.D.. INTRODUCTION ACC/AHA GUIDELINE UPDATE FOR CORONARY ARTERY BYPASS GRAFT SURGERY (JACC 2004; 44: AND CIRCULATION.
2 Year Clinical Outcomes from the Pivotal RESOLUTE US Study Laura Mauri MD, MSc on behalf of the RESOLUTE US Investigators Brigham and Women’s Hospital.
Unrestricted Use of Drug-Eluting Stents Compared with Bare-Metal Stents in Routine Clinical Practice: Findings From the National Heart, Lung, and Blood.
Guidelines on Perioperative Cardiovascular Evaluation and Care for Noncardiac Surgery 2007 ACC/AHA and 2009 ESC GUIDELINES.
New guidelines for CABG
Carotid Artery Stenosis: Stenting vs. Endarterectomy Városmajor Study. L. Entz,, E.Dósa, K. Hüttl. Department of Cardiovascular Surgery, Semmelweis University,
Endarterectomy versus Stenting in Patients with Symptomatic Severe Carotid Stenosis Dr. Quan, Dr. Mirhashemi, Dr. Chiang N Engl J Med 2006; 355:
ACUTE CORONARY SYNDROMES:
Arterial Revascularization Therapies Part II: a non- randomized comparison of contemporary PCI and coronary artery bypass grafting (CABG) in patients with.
INTRODUCTION Dual antiplatelet therapy is a cornerstone of medical therapy for patients undergoing percutaneous coronary intervention (PCI) for coronary.
Basel Stent Cost-Effectiveness (BASKET) Trial BASKET Trial Presented at The European Society of Cardiology Hotline Session 2005 Presented by Dr. Matthias.
LONG-TERM OUTCOMES OF PERCUTANEOUS CORONARY INTERVENTION FOR UNPROTECTED LEFT MAIN CORONARY ARTERY DISEASE: INITIAL CLINICAL EXPERIENCE. Graidis Ch. 1,
PRACTICAL RECOMMENDATIONS ON ANTI- THROMBOTIC TREATMENT IN PATIENTS TREATED WITH DRUG-ELUTING STENTS Giuseppe Biondi-Zoccai Ospedale S. Giovanni Battista.
Is the Decision-Making after Failure of CTO Angioplasty Same? Infarct Related CTO or Non- Infarct Related CTO (Continue the Procedure in Other Vessel or.
Ischemia Management with Accupril Post Bypass Graft via Inhibition of Angiotensin Converting Enzyme IMAGINEIMAGINE Presented at The European Society of.
An MI, a Stent, Bleeding, and Surgery! What Do I Do? COPYRIGHT © 2016, ALL RIGHTS RESERVED From the Publishers of.
Is there any role for intravascular ultrasound in bifurcation lesions? Giuseppe Biondi-Zoccai, MD University of Turin, Turin, Italy.
VASIL VELCHEV ST. ANNA HOSPITAL, SOFIA. Conflict of interest:
CAROTID ARTERY ENDARTHERECTOMY &INTERVENTION
Evaluation of the Cardiac Patient Before Non-Cardiac Surgery
2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease Developed in Collaboration with.
Date of download: 6/25/2016 Copyright © The American College of Cardiology. All rights reserved. From: Readmissions After Carotid Artery Revascularization.
Date of download: 6/27/2016 Copyright © The American College of Cardiology. All rights reserved. From: Use and Outcomes of Triple Therapy Among Older Patients.
Faramarz Amiri MD IUMS.  Severe carotid disease (defined as >80%) 8–12%  Severe carotid disease (>70%) in those with three vessel or left main coronary.
Date of download: 7/1/2016 Copyright © The American College of Cardiology. All rights reserved. From: The Scope of Coronary Heart Disease in Patients With.
Date of download: 7/2/2016 Copyright © The American College of Cardiology. All rights reserved. From: Long-Term Outcomes of Older Diabetic Patients After.
Date of download: 7/3/2016 Copyright © The American College of Cardiology. All rights reserved. From: The Uncertain Value of Renal Artery Interventions:
Date of download: 7/6/2016 Copyright © The American College of Cardiology. All rights reserved. From: Long-Term Clinical Results Following Stenting of.
Date of download: 7/9/2016 Copyright © The American College of Cardiology. All rights reserved. From: ACC/AHA guidelines for percutaneous coronary intervention.
From: Sustained Safety and Effectiveness of Paclitaxel-Eluting Stents for Femoropopliteal Lesions: 2-Year Follow-Up From the Zilver PTX Randomized and Single-Arm.
Date of download: 9/19/2016 Copyright © The American College of Cardiology. All rights reserved. From: Characteristics and Long-Term Outcomes of Percutaneous.
Date of download: 11/12/2016 Copyright © The American College of Cardiology. All rights reserved. From: Efficacy and Safety of Dual Antiplatelet Therapy.
Dr. Quan, Dr. Mirhashemi, Dr. Chiang
Stepwise approach to assessing cardiac patient risk for noncardiac surgery. (Reproduced, with permission, from Fleisher LA et al. ACC/AHA 2007 Guidelines.
Stepwise approach to assessing cardiac patient risk for noncardiac surgery. (Reproduced, with permission, from Fleisher LA et al. ACC/AHA 2007 Guidelines.
What´s New in the Literature on Transradial Intervention
The MASS-DAC Study.
Algorithm for preoperative management of patients taking antiplatelet therapy. ACS, acute coronary syndrome; BMS, bare metal stent; DES, drug-eluting stent;
PCI related in-hospital mortality based on race and gender in the USA
Figure 3 One-year adverse events (death, post-discharge myocardial infarction, revascularization) after PCI according to patients who (A) would not have.
Debate: What Does the Future Hold for the Treatment of Unprotected Left Main Disease? More PCI No More Routine Surgery Ron Waksman, MD, FACC Washington.
Single Stage CABG and Peripheral Arterial Bypass for Combined Coronary and Peripheral Arterial Disease Divya Arora, Ashok Chahal and Shamsher Singh Lohchab.
The Hidden Cost of Underutilizing PCI for Chronic Total Occlusions
Stenting of Coronary Arteries in Non Stress/Benestent Disease
Catheter-Based Treatment of Coronary Artery Disease
Glenn N. Levine et al. JACC 2016;68:
Glenn N. Levine et al. JACC 2016;68:
Bern-Rotterdam Registry Published in the Lancet
Giuseppe Biondi Zoccai, MD
2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease  Glenn N. Levine, MD, FACC, FAHA,
P. Foëx  British Journal of Anaesthesia 
3-Year Clinical Outcomes From the RESOLUTE US Study
Peter K. Smith, MD  The Journal of Thoracic and Cardiovascular Surgery 
Peter K. Smith, MD  The Annals of Thoracic Surgery 
NIPPON Trial design: Patients undergoing percutaneous coronary intervention were randomized to short-term dual antiplatelet therapy (DAPT) (6 months; n.
Effect of PCI on 1-year risk of all-cause mortality and major cardiovascular outcomes. CABG, coronary artery bypass grafting; CI, confidence interval (bars);
Incidence and management of restenosis after treatment of unprotected left main disease with drug-eluting stents: 70 restenotic cases from a cohort of.
(p < for noninferiority)
Markov model scheme. Markov model scheme. Patients start (state 0) with uncomplicated PCI revascularisation; then cycle between health states until death.
IVUS-XPL Trial design: Patients undergoing drug-eluting stent implantation for long coronary lesions were randomized to IVUS-guided PCI (n = 700) vs. angiography-guided.
Glenn N. Levine et al. JACC 2011;58:e44-e122
Lee A. Fleisher et al. JACC 2014;64:e77-e137
Effect of PCI on 3 to 5-year risk of all-cause mortality and major cardiovascular outcomes. CABG, coronary artery bypass grafting; CI, confidence interval.
P2Y12 receptor inhibitor therapy for secondary prevention of patients with stable coronary artery disease. P2Y12 receptor inhibitor therapy for secondary.
Presentation transcript:

Asymptomatic Carotid Surgery Trial ACST-2 Collaborators Meeting 2014 Pembroke College, Oxford Is recent coronary stenting a problem (or an opportunity) for enrolling the patient in the trial? Valerio Tolva MD, PhD Istituto Auxologico Italiano IRCCS Deparment of Surgery Vascular Surgery (Head: Renato Casana MD) Milan, Italy

Handling a patient with recent coronary stenting and carotid stenosis is like a sailing race: You can head straight forcing the upwind : with double therapy perform CAS You can run on a beam wind and then upwind : stop double therapy and perform CEA Crews have guidelines for the right approach to a race… can we create guidelines using the data of the Trial?

“the prevalence of severe carotid disease (>80% stenosis of ICA) among patients undergoing Percutaneous Coronary Intervention (PCI)/Open Heart Surgery (OHS) is estimated to be 6% to 12%.” “…optimal treatment of patients with concurrent carotid and coronary artery disease remains unresolved despite >110 publications during the last 30 years reporting results in 9,000 patients.” Overview of the Nationwide Inpatient Sample (NIS) of the Healthcare Cost and Utilization Project (HCUP), from Timaran et al. J Vasc Surg 2009

Coronary revascularization before non cardiac surgery is believed to decrease the peri- and post-operative risk in selected patients Fleisher LA et al. ACC/AHA 2007 Guidelines on perioperative cardiovascular evaluation. J Am Coll Cardiol 2007 The frequency of major non cardiac surgery in the year after Drug Eluting Stent placement is >4-5% Berger et al. Pre-Operative DES in EVENT Registry. J Am Coll Cardiol Intv Van Kuijk et al. Timing of non cardiac surgery after coronary artery stenting. Am J Cardiol 2009

Do PCI/Open Heart Surgery affect the rate of Major Adverse Cardiovascular Events in patient with carotid artery stenosis? UnprotectedProtected Shishehbor et al. JACC. 2013

Do PCI affect the rate of Major Adverse Cardiovascular Events in patients with carotid artery stenosis? Dashed line: CAS without PCI Solid line: CAS with PCI Tomai et al JACC:Cardiovasc Interv

Why do we consider Percutaneous Coronary Intervention a bias? CEA without Double AntiPlatelet Therapy RELATED COMPLICATIONS: death, MI, stent thrombosis Van Kuijk et al. Am.J.Cardiol, 2009

Suspension of Double AntiPlatelet Therapy after Percutaneous Coronary Intervention (PCI) is associated with the risk of peri- operative Major Adverse Cardiovascular Events due to stent thrombosis Stent thrombosis is a multifactorial process Surface coating: Drug Eluting Stents (DES), Bare Metal Stents (BMS) Stent diameter Stent length Vessel diameter Left ventricular ejection fraction Metabolic syndrome

Stent-related decision making: PCI with BMS: The European Society of Cardiology + ACC/AHA recommends DAPT for a minimum of 6 weeks after PCI PCI with DES: The European Society of Cardiology + ACC/AHA recommends DAPT for a minimum of 1 year Always consider the time interval in patients with coronary and carotid lesions Avoiding DES in patients scheduled for carotid or aortic surgery can save 6-9 months. The cardiovascular crew

Why do we consider PCI a bias? CEA with Double AntiPlatelet Therapy RELATED COMPLICATIONS: Severe bleeding (life-threatening, requiring surgical intervention, transfusion)

Bleeding and Double AntiPlatelet Therapy Bleeding and hematoma of the neck are the leading causes of in-hospital morbidity after carotid surgery Major Adverse Cardiovascular Events and bleeding are the main predictors for unplanned hospital readmission within 30 days of CEA Ho KJ et al. Predictors and consequences of unplanned hospital readmission. J Vasc Surg 2014

A decision-making flowchart? Enrollable carotid stenosis Is DAPT still running? NO YES ENROLL THE PATIENT BMS Wait 3 months from PCI DES Symptoms? Unstable instrumental findings? CAS Wait 9 months Recent PCI (< 3 months)

The cut off for enrolling the patient is 3 months. In asymptomatic patients, cardiac timing is the leading priority regarding carotid stenosis Carotid endarterectomy is the bias for enrollment if the patient is taking double therapy As DES and BMS have different safety periods, a tailored stenting in patients with tandem lesions (coronary and carotid) must be considered. Recruitment Centers with CathLab can enroll 6-12% of patients after PCI (30-60 pts/year) Should we look at this subgroup or will the trial give the answers? Key points

Before making a mistake… …Join the Trial and choose the best route